What is Eli Lilly and Company (LLY)?

Eli Lilly and Company (LLY) is a stock in the Healthcare sector, Drug Manufacturers - General industry. View full analysis on Stocks360.

What is the current price of LLY?

The current price of LLY is $1,281.91. Prices are updated in real time on Stocks360.

What is LLY's price-to-earnings (PE) ratio?

LLY's trailing twelve-month PE ratio is 42.89, based on current price and earnings per share data available on Stocks360.

What is LLY's market capitalization?

LLY's market capitalization is $1,206,734,951,870.00, placing it in the large-cap tier.

Does LLY pay a dividend?

Yes. LLY has a trailing twelve-month dividend yield of 0.01%. Dividend data is sourced from financial market providers and displayed on Stocks360.

Eli Lilly and Company (LLY)

Stock analysis · NYSE · Healthcare · Drug Manufacturers - General

$1,281.91

Market Cap

$1.21T

PE (TTM)

42.89

EPS (TTM)

N/A

Dividend Yield

0.52%

Beta

0.45

Day Range

$1,272.07 – $1,297.92

52-wk Range

$809.63 – $1,321.21

Avg Volume

N/A

Volume

1.85M

Eli Lilly and Company (LLY) is a publicly traded company in the Healthcare sector. Latest price: $1,281.91. Market cap $1.21T. Trailing PE 42.89. Dividend yield 0.52%. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-28 · $820.10 2026-10-27 · $1,281.91 (+56.31%)

Earnings

Most Recent

Aug 5, 2026

EPS $8.38 vs est. $6.40

Beat by $1.98

Next Earnings

Oct 29, 2026

EPS estimate $5.68

Proprietary Signals

Signal snapshot temporarily unavailable.

About Eli Lilly and Company

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, H…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	42.89×
P/S (TTM)	15.15×
P/B	33.77×
PEG	0.45×
P/FCF (TTM)	60.17×
EV / EBITDA	28.93×
EV / Sales	15.73×
Earnings Yield	2.33%
Free Cash Flow Yield	1.66%
Dividend Yield	0.52%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$1.25T
Revenue (TTM)	$79.67B
Net Income (TTM)	$28.18B
Free Cash Flow (TTM)	$18.97B
Net Debt	$46.02B
Working Capital	$16.93B
Gross Margin	83.40%
Operating Margin	49.72%
Net Margin	33.53%
Return on Equity	92.58%
Return on Invested Capital	31.00%